If larger studies confirm our findings, TNBC therefore may be included within clinical criteria for BRCA1 and BRCA2 mutation screening, and additional cases may be assessed not only if they present with early-onset of the disease or have a familial aggregation of breast and/or ovarian cancer. The gene discussed is BRCA1; the disease is ovarian cancer.